



# Fintepla (fenfluramine) Prior Authorization with Quantity Limit Program Summary

This program applies to FlexRx Closed, FlexRx Open, FocusRx, GenRx Closed, GenRx Open, Health Insurance Marketplace, and KeyRx formularies.

This is a FlexRx Standard and GenRx Standard program.

The BCBS MN Step Therapy Supplement also applies to this program for all Commercial/HIM lines of business.

## POLICY REVIEW CYCLE

**Effective Date**  
06-01-2024

**Date of Origin**  
01-01-2021

## FDA APPROVED INDICATIONS AND DOSAGE

Agent(s)	FDA Indication(s)	Notes	Ref#
Fintepla®  (fenfluramine)  Oral solution	Treatment of seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older		1

See package insert for FDA prescribing information: <https://dailymed.nlm.nih.gov/dailymed/index.cfm>

## CLINICAL RATIONALE

Dravet Syndrome	Dravet syndrome (DS) is a severe form of epilepsy with an onset of recurrent, prolonged seizures in infancy that are often triggered by fever or overheating. DS is characterized by lifelong comorbidities, including neurodevelopmental problems and intellectual disability.(2,3,4,9) Mutations in the alpha-1 subunit of the voltage-gated sodium channel (SCN1A) gene are identified in at least 80% of patients with DS.(2,3,9) Status epilepticus is common and is one of the leading causes of premature mortality seen with DS. Patients with DS have an elevated risk of premature mortality, with the most common cause being sudden unexpected death in epilepsy (SUDEP).(2,3,4) Other types of seizures appear before age 5 years and include myoclonic, focal, and atypical absence seizures.(2,3,9) Valproate is considered first-line therapy, with clobazam added if needed.(2,3,4,9) Additional agents include stiripentol, topiramate, cannabidiol, and fenfluramine.(3,4,9) For patients with symptoms refractory to drug therapy, ketogenic diet and vagal nerve stimulation may be beneficial.(2,3,4,9)
Lennox-Gastaut Syndrome	Lennox-Gastaut syndrome (LGS) is a severe form of epilepsy involving several seizure types, with an onset during infancy or early childhood. Many causes of LGS have been identified, including genetic disorders, trauma, cortical malformations, perinatal hypoxia, and meningitis. Tonic, atonic, and atypical absence seizures are the most common seizure types associated with LGS. Clinical features that may be present include cognitive dysfunction, behavioral abnormalities, and neurodevelopmental impairment. Management of LGS is difficult because it is refractory to many treatments, and no specific therapy is effective for all patients. Valproate is generally considered first-line therapy, and if monotherapy is ineffective another drug such as lamotrigine or rufinamide is added to valproate therapy.(7,8) Alternative adjunctive antiseizure medications include topiramate, clobazam, cannabidiol, fenfluramine, or felbamate.(8) Additional therapies, for patients who do not respond to antiseizure medications, include the ketogenic diet and vagal nerve stimulation.(7,8)

Efficacy	<p>The effectiveness of fenfluramine for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older was established in two randomized, double-blind, placebo-controlled trials in patients 2 to 18 years of age. Study 1 (N = 117) compared a 0.7 mg/kg/day and a 0.2 mg/kg/day dose of fenfluramine with placebo in patients who were NOT receiving stiripentol. Study 2 (N = 85) compared a 0.4 mg/kg/day dose of fenfluramine with placebo in patients who were receiving stiripentol and either clobazam, valproate, or both. In both studies, patients had a clinical diagnosis of Dravet syndrome and were inadequately controlled on at least one antiepileptic drug (AED) or other antiseizure treatment including vagal nerve stimulation or a ketogenic diet. In Study 1, 98% of patients were taking 1-4 concomitant AEDs; in Study 2, 100% were taking 2-4 concomitant AEDs.(1)</p> <p>The primary efficacy endpoint in both studies was the change from baseline in the frequency of convulsive seizures per 28 days during the treatment period. For Study 1, the percent reduction in monthly convulsive seizure frequency was 70% for the 0.7 mg/kg/day dose (p less than 0.001) and 31.7% for the 0.2 mg/kg/day dose (p=0.043); for Study 2 it was 59.5% reduction (p less than 0.001). A reduction in convulsive seizures was observed within 3-4 weeks of starting fenfluramine, and the effect remained generally consistent over the 14- or 15-week treatment period.(1)</p> <p>A secondary endpoint was longest seizure-free interval, for which the median longest seizure-free intervals in the 0.7 mg/kg/day, 0.4 mg/kg/day, and 0.2 mg/kg/day groups were 25 days, 22 days, and 15 days, respectively.(5,6)</p> <p>The effectiveness of fenfluramine for the treatment of seizures associated with LGS in patients 2 years of age and older was established in a randomized, double-blind, placebo-controlled trial in patients 2 to 35 years of age. Study 3 (N=263) compared a 0.7 mg/kg/day and a 0.2 mg/kg/day dose of fenfluramine with placebo in patients with a diagnosis of LGS who were inadequately controlled on at least one antiepileptic drug (AED) or other antiseizure treatment including vagal nerve stimulation and/or a ketogenic diet.(1)</p> <p>The primary efficacy endpoint was the median percent change from baseline (reduction) in the frequency of seizures per 28 days during the treatment period. The median percent change from baseline (reduction) in the frequency of seizures per 28 days was significantly greater for the 0.7 mg/kg/day group compared with placebo (23.7%; p=0.0037). The effect remained generally consistent over the 14-week treatment period.(1)</p>
Safety	<p>Fintepla carries a boxed warning for valvular heart disease and pulmonary arterial hypertension. There is an association between serotonergic drugs with 5-HT<sub>2B</sub> receptor agonist activity, including fenfluramine, and valvular heart disease and pulmonary arterial hypertension. Echocardiogram assessments are required before, during, and after treatment with Fintepla; benefits versus risks of initiating or continuing must be considered based on echocardiogram findings. Because of these risks, Fintepla is available only through the Fintepla REMS program.(1)</p> <p>Fintepla has the following contraindications:(1)</p> <ul style="list-style-type: none"> <li>• Concomitant use of, or within 14 days of the administration of, monoamine oxidase inhibitors because of an increased risk of serotonin syndrome.</li> <li>• Hypersensitivity to fenfluramine or any of the excipients in Fintepla.</li> </ul>

## REFERENCES

Number	Reference
1	Fintepla prescribing information. Zogenix, Inc. December 2023.
2	Wirrell EC, Laux L, Donner E, et al. Optimizing the Diagnosis and Management of Dravet Syndrome: Recommendations from a North American Consensus Panel. <i>Pediatr Neurol.</i> 2017;68:18-34.

Number	Reference
3	Sullivan J, Knupp K, Wirrell E, et al. Dravet Syndrome. National Organization for Rare Disorders (NORD). Last updated July 2020. Available at <a href="https://rarediseases.org/rare-diseases/dravet-syndrome-spectrum/">https://rarediseases.org/rare-diseases/dravet-syndrome-spectrum/</a> .
4	Andrade DM, Nascimento FA, et al. Dravet Syndrome: Management and Prognosis. UpToDate. Last updated November 2022. Literature review current through December 2023.
5	Lagae L, Sullivan J, Knupp K, et al. Fenfluramine Hydrochloride for the Treatment of Seizures in Dravet Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Lancet. 2019;394(10216):2243-2254.
6	Nabbout R, Mistry A, Zuberi S, et al. Fenfluramine for Treatment-Resistant Seizures in Patients with Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial. JAMA Neurol. 2020;77(3):300-308.
7	Wheeless JW. Lennox-Gastaut Syndrome. National Organization for Rare Disorders (NORD). Last updated June 2020. Available at <a href="https://rarediseases.org/rare-diseases/lennox-gastaut-syndrome/">https://rarediseases.org/rare-diseases/lennox-gastaut-syndrome/</a> .
8	Wilfong A, et al. Lennox-Gastaut syndrome. UpToDate. Last updated June 2023. Literature review current through December 2023.
9	Wirrell E, Hood V, Knupp KG, et al. International consensus on diagnosis and management of Dravet syndrome. Epilepsia. 2022;63(7):1761-1777.

### POLICY AGENT SUMMARY PRIOR AUTHORIZATION

Target Brand Agent(s)	Target Generic Agent(s)	Strength	Targeted MSC	Available MSC	Final Age Limit	Preferred Status
Fintepla	fenfluramine hcl oral soln	2.2 MG/ML	M ; N ; O ; Y	N		

### POLICY AGENT SUMMARY QUANTITY LIMIT

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	QL Amount	Dose Form	Day Supply	Duration	Addtl QL Info	Allowed Exceptions	Targeted NDCs When Exclusions Exist
Fintepla	Fenfluramine HCl Oral Soln 2.2 MG/ML	2.2 MG/ML	360	mLs	30	DAYS			

### CLIENT SUMMARY – PRIOR AUTHORIZATION

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
Fintepla	fenfluramine hcl oral soln	2.2 MG/ML	FlexRx Closed ; FlexRx Open ; FocusRx ; GenRx Closed ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx

## CLIENT SUMMARY – QUANTITY LIMITS

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
Fintepla	Fenfluramine HCl Oral Soln 2.2 MG/ML	2.2 MG/ML	FlexRx Closed ; FlexRx Open ; FocusRx ; GenRx Closed ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx

## PRIOR AUTHORIZATION CLINICAL CRITERIA FOR APPROVAL

Module	Clinical Criteria for Approval
	<p><b>Initial Evaluation</b></p> <p><b>Target Agent(s)</b> will be approved when ALL of the following are met:</p> <ol style="list-style-type: none"> <li>1. ONE of the following:           <ol style="list-style-type: none"> <li>A. BOTH of the following:               <ol style="list-style-type: none"> <li>1. ONE of the following:                   <ol style="list-style-type: none"> <li>A. The patient has been treated with the requested agent (starting on samples is not approvable) within the past 90 days <b>OR</b></li> <li>B. The prescriber states the patient has been treated with the requested agent (starting on samples is not approvable) within the past 90 days AND is at risk if therapy is changed <b>AND</b></li> </ol> </li> <li>2. The patient has an FDA labeled indication for the requested agent <b>OR</b></li> </ol> </li> <li>B. BOTH of the following:               <ol style="list-style-type: none"> <li>1. ONE of the following:                   <ol style="list-style-type: none"> <li>A. If the patient has a diagnosis of Dravet syndrome (DS), then ONE of the following:                       <ol style="list-style-type: none"> <li>1. The patient has tried and had an inadequate response to TWO generic antiseizure agents used in the treatment of DS (e.g., valproate, clobazam, stiripentol, topiramate) <b>OR</b></li> <li>2. The patient has an intolerance or hypersensitivity to TWO generic antiseizure agents used in the treatment of DS (e.g., valproate, clobazam, stiripentol, topiramate) <b>OR</b></li> <li>3. The patient has an FDA labeled contraindication to ALL generic antiseizure agents used in the treatment of DS (e.g., valproate, clobazam, stiripentol, topiramate) <b>OR</b></li> <li>4. The patient is currently being treated with the requested agent as indicated by ALL of the following:                           <ol style="list-style-type: none"> <li>A. A statement by the prescriber that the patient is currently taking the requested agent <b>AND</b></li> <li>B. A statement by the prescriber that the patient is currently receiving a positive therapeutic outcome on requested agent <b>AND</b></li> <li>C. The prescriber states that a change in therapy is expected to be ineffective or cause harm <b>OR</b></li> </ol> </li> <li>5. The prescriber has provided documentation that ALL generic antiseizure agents used in the treatment of DS (e.g., valproate, clobazam, stiripentol, topiramate) cannot be used due to a documented medical condition or comorbid condition that is likely to cause an adverse reaction, decrease ability of the patient to achieve or maintain reasonable functional ability in performing daily activities or cause physical or mental harm <b>OR</b></li> </ol> </li> <li>B. If the patient has a diagnosis of Lennox-Gastaut syndrome (LGS), then ONE of the following:                       <ol style="list-style-type: none"> <li>1. The patient has tried and had an inadequate response to TWO generic antiseizure agents used in the treatment of LGS (e.g., valproate, lamotrigine, rufinamide, topiramate, clobazam, felbamate) <b>OR</b></li> </ol> </li> </ol> </li> </ol> </li> </ol> </li> </ol>

Module	Clinical Criteria for Approval
	<ol style="list-style-type: none"> <li>2. The patient has an intolerance or hypersensitivity to TWO generic antiseizure agents used in the treatment of LGS (e.g., valproate, lamotrigine, rufinamide, topiramate, clobazam, felbamate) <b>OR</b></li> <li>3. The patient has an FDA labeled contraindication to ALL generic antiseizure agents used in the treatment of LGS (e.g., valproate, lamotrigine, rufinamide, topiramate, clobazam, felbamate) <b>OR</b></li> <li>4. The patient is currently being treated with the requested agent as indicated by ALL of the following: <ol style="list-style-type: none"> <li>A. A statement by the prescriber that the patient is currently taking the requested agent <b>AND</b></li> <li>B. A statement by the prescriber that the patient is currently receiving a positive therapeutic outcome on requested agent <b>AND</b></li> <li>C. The prescriber states that a change in therapy is expected to be ineffective or cause harm <b>OR</b></li> </ol> </li> <li>5. The prescriber has provided documentation that ALL generic antiseizure agents used in the treatment of LGS (e.g., valproate, lamotrigine, rufinamide, topiramate, clobazam, felbamate) cannot be used due to a documented medical condition or comorbid condition that is likely to cause an adverse reaction, decrease ability of the patient to achieve or maintain reasonable functional ability in performing daily activities or cause physical or mental harm <b>OR</b> <ol style="list-style-type: none"> <li>C. The patient has another FDA labeled indication for the requested agent and route of administration <b>AND</b></li> </ol> </li> </ol> <ol style="list-style-type: none"> <li>2. If the patient has an FDA labeled indication, then ONE of the following: <ol style="list-style-type: none"> <li>A. The patient's age is within FDA labeling for the requested indication for the requested agent <b>OR</b></li> <li>B. There is support for using the requested agent for the patient's age for the requested indication <b>AND</b></li> </ol> </li> <li>2. If the patient has a diagnosis of seizures associated with Dravet syndrome (DS) or Lennox-Gastaut syndrome (LGS), the requested agent will NOT be used as monotherapy for seizure management <b>AND</b></li> <li>3. An echocardiogram assessment will be obtained before and during treatment with the requested agent to evaluate for valvular heart disease and pulmonary arterial hypertension <b>AND</b></li> <li>4. The prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis <b>AND</b></li> <li>5. The patient does NOT have any FDA labeled contraindications to the requested agent</li> </ol> <p><b>Length of Approval:</b> 12 months</p> <p>NOTE: If Quantity Limit applies, please refer to Quantity Limit Criteria.</p> <p><b>Renewal Evaluation</b></p> <p><b>Target Agent(s)</b> will be approved when ALL of the following are met:</p> <ol style="list-style-type: none"> <li>1. The patient has been previously approved for the requested agent through the plan's Prior Authorization process [Note: patients not previously approved for the requested agent will require initial evaluation review] <b>AND</b></li> <li>2. The patient has had clinical benefit with the requested agent <b>AND</b></li> <li>3. If using for seizure management associated with Dravet syndrome (DS) or Lennox-Gastaut syndrome (LGS), the requested agent will NOT be used as monotherapy <b>AND</b></li> <li>4. An echocardiogram assessment will be obtained during treatment with the requested agent, to evaluate for valvular heart disease and pulmonary arterial hypertension <b>AND</b></li> </ol>

Module	Clinical Criteria for Approval
	<p>5. The prescriber is a specialist in the area of the patient’s diagnosis (e.g., neurologist) or the prescriber has consulted with a specialist in the area of the patient’s diagnosis <b>AND</b></p> <p>6. The patient does NOT have any FDA labeled contraindications to the requested agent</p> <p><b>Length of Approval:</b> 12 months</p> <p>NOTE: If Quantity Limit applies, please refer to Quantity Limit Criteria.</p>

**QUANTITY LIMIT CLINICAL CRITERIA FOR APPROVAL**

Module	Clinical Criteria for Approval
	<p><b>Quantity limit for the Target Agent(s)</b> will be approved when ONE of the following is met:</p> <ol style="list-style-type: none"> <li>1. The requested quantity (dose) does NOT exceed the program quantity limit <b>OR</b></li> <li>2. ALL of the following: <ol style="list-style-type: none"> <li>A. The requested quantity (dose) exceeds the program quantity limit <b>AND</b></li> <li>B. The requested quantity (dose) does NOT exceed the maximum FDA labeled dose for the requested indication <b>AND</b></li> <li>C. The requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does NOT exceed the program quantity limit</li> </ol> </li> </ol> <p><b>Length of Approval:</b> up to 12 months</p>